Becton Dickinson Earns $2.52 Per Share As Quarterly Legal Charges Shrink

BD expects fiscal 2027 adjusted earnings of $13.10 to $13.30 per share, with sales growing a few percent.

Share
Becton Dickinson Earns $2.52 Per Share As Quarterly Legal Charges Shrink

Becton Dickinson, which makes medical supplies and devices, earned $2.52 per diluted share from continuing operations in its fourth quarter, versus $1.20 a year earlier—a 110% reported increase. The unaudited results, announced Thursday and furnished in an SEC filing, paired higher sales with lower production costs and smaller legal charges.

Quarterly revenue reached $5,274 million, growing 5.4% as reported and 5.6% without currency movements. Adjusted earnings rose 27.3% to $4.15 per diluted share from $3.26, a smaller increase than the standard-accounting result.

The cost of products sold declined to $2,581 million from $2,639 million. BD received a $66 million benefit from refunds of tariffs imposed under the International Emergency Economic Powers Act, recorded primarily against that cost line. Quarterly charges for product liability and certain other legal matters were $45 million, compared with $232 million a year earlier.

Operating income reached $1,032 million, up 92.5% from $536 million. Restructuring costs also fell, to $35 million from $84 million.

The annual picture was more mixed. Fiscal 2026 revenue totaled $19,457 million, up 4.9% as reported and 3.9% excluding currency movements. Continuing-operations earnings were $5.06 per diluted share, compared with $3.81; adjusted earnings were $12.70, versus $11.90.

Net income including discontinued businesses fell 31.7% to $1,145 million from $1,678 million. Discontinued operations produced a $271 million loss, against a $577 million profit the previous year.

Four Businesses After The Waters Separation

BD completed the separation of Biosciences and Diagnostic Solutions and that business's combination with Waters on February 9, 2026. Those results now sit in discontinued operations, and earlier comparisons have been revised to match.

Tom Polen, BD's chairman, CEO and president, said fiscal 2026 completed the transformation to “a more focused MedTech company.”

BD's products include syringes, infusion pumps, blood-collection systems and surgical implants, sold to hospitals, clinics and other healthcare customers. Its remaining operations span Medical Essentials, Connected Care, BioPharma Systems and Interventional.

Interventional posted quarterly sales of $1,472 million, up 7.6% both as reported and without currency movements. Medical Essentials generated $1,786 million, up 5.9% on both bases, while BioPharma Systems brought in $748 million, rising 6.5% as reported and 7.0% excluding currency effects.

Connected Care grew more slowly: revenue of $1,269 million was up 1.6% as reported and 2.1% without currency movements. Within that business, medication-management sales fell 2.3% as reported, while advanced patient monitoring grew 15.0%; excluding currency effects, those changes were a 2.2% decline and 17.3% growth, respectively.

U.S. quarterly sales reached $3,204 million, up 4.3%. International revenue was $2,070 million, growing 7.0% as reported and 7.6% without currency movements.

More Cash, Slower Sales Outlook

For fiscal 2027, BD forecasts adjusted diluted earnings of $13.10 to $13.30 per share, representing growth of 3.1% to 4.7% from fiscal 2026. Management expects sales to grow a few percent, both as reported and excluding currency movements.

Continuing operations generated $3,605 million in cash during fiscal 2026, up 30.0%. After $672 million of capital spending, free cash flow was $2,933 million, up 42.5% from $2,058 million. That measure does not deduct obligations such as debt service.

BD spent $2,433 million repurchasing shares, compared with $1,000 million the previous year, and paid $1,161 million in dividends. The company also received a $3,916 million distribution from the spun-off entity and made $2,696 million in debt payments.

The company announced a U.S. government partnership under which it intends to invest $19 billion domestically over several years, including $3 billion for manufacturing expansion. The agreement provides relief from future Section 232 tariffs on covered products and inputs, dependent on the final tariff scope and implementation and BD meeting agreed milestones.

BD plans to hold its 2026 Investor Day at the New York Stock Exchange on December 10.

Sources